Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 19, 2023 08:30 ET | Source: Biomea Fusion, Inc.

Biomea Fusion to Present Late Breaking Data from Ongoing Phase II Trial, COVALENT-111, Evaluating BMF-219 in Patients with Type 2 Diabetes, at the ADA 83rd Scientific Sessions 2023 in June

New clinical data from COVALENT-111 will be featured during the Late-Breaking Poster Presentations at the Scientific SessionsBiomea to hold an investor and KOL event during the Scientific Sessions ...
April 13, 2023 16:30 ET | Source: Biomea Fusion, Inc.

Biomea Fusion To Present Two Preclinical Posters at the 114th AACR Annual Meeting

Abstract 473 highlights the dose dependent reduction of menin target genes in ex vivo chronic lymphocytic leukemia (CLL) patient samples treated with BMF-219, an investigational covalent inhibitor....
April 13, 2023 09:00 ET | Source: Biomea Fusion, Inc.

Biomea Fusion Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

REDWOOD CITY, Calif., April 13, 2023 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or the “Company”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and...
March 29, 2023 23:15 ET | Source: Biomea Fusion, Inc.

Biomea Fusion Announces Pricing of Upsized Public Offering of Common Stock

REDWOOD CITY, Calif., March 29, 2023 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing novel...
March 29, 2023 06:30 ET | Source: Biomea Fusion, Inc.

Biomea Fusion Announces Proposed Public Offering of Common Stock

REDWOOD CITY, Calif., March 29, 2023 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing novel...
March 28, 2023 16:02 ET | Source: Biomea Fusion, Inc.

Biomea Fusion Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Highlights

Expanded clinical development footprint of BMF-219, the company’s lead investigational, orally administered, covalent menin inhibitor, to eight liquid and solid tumor indications and type 2 diabetes...
March 28, 2023 08:00 ET | Source: Biomea Fusion, Inc.

Biomea Fusion Announces Positive Data from Initial Cohorts of Ongoing Phase II Study (COVALENT-111) of BMF-219 in Patients with Type 2 Diabetes; 100 mg Cohort 3 Demonstrated an 89% Response Rate and 1% Median Reduction in HbA1c at Day 28

In Cohort 3, after 4 weeks of once-daily 100 mg dosing with the investigational, oral covalent menin inhibitor, BMF-219, 89% of patients achieved a reduction in A1c, 78% of patients achieved at least...
March 23, 2023 08:00 ET | Source: Biomea Fusion, Inc.

Biomea Fusion to Host Conference Call and Webcast to Discuss Initial Phase II Clinical Data for BMF-219 in Subjects with Type 2 Diabetes on March 28th, 2023 at 8:30 a.m. ET

REDWOOD CITY, Calif., March 23, 2023 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing novel...
March 02, 2023 08:30 ET | Source: Biomea Fusion, Inc.

Biomea Fusion To Participate In Upcoming Investor Events

REDWOOD CITY, Calif., March 02, 2023 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a biopharmaceutical company focused on the discovery and development of covalent small...
January 17, 2023 08:00 ET | Source: Biomea Fusion, Inc.

Biomea Fusion Doses First Patient in Phase I/Ib Clinical Trial (COVALENT-102) of BMF-219 in KRAS Mutant Solid Tumors

BMF-219 is the first menin inhibitor to be clinically studied in patients with KRAS-mutated non-small cell lung cancer (NSCLC), colorectal cancer (CRC) and pancreatic ductal adenocarcinoma (PDAC)A...